Glenmark Pharma
Ticker >

Glenmark Pharma share price

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK BSE: 532296 SECTOR: Pharmaceuticals & Drugs  188k   1k   209

1023.90
-18.80 (-1.80%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1038.7

Today's Low

₹ 1020.6

52 Week High

₹ 1068

52 Week Low

₹ 507.65

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 28893.25 Cr.

Enterprise Value

₹ 31955.85 Cr.

No. of Shares

28.22 Cr.

P/E

69.43

P/B

1.57

Face Value

₹ 1

Div. Yield

0.24 %

Book Value (TTM)

₹  650.55

CASH

₹ 93.79 Cr.

DEBT

₹ 3156.4 Cr.

Promoter Holding

46.64 %

EPS (TTM)

₹  14.75

Sales Growth

0.97%

ROE

6.98 %

ROCE

8.58%

Profit Growth

-39.49 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glenmark Pharmaceuticals Ltd.

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

Index Presence

The company is present in 19 Indices.

NIFTYALPHA

Nifty Alpha 50
47743.75
  -295.550000000003 (-0.615225450828805%)

NIFTY500

Nifty 500
20385.2
  60.5 (0.297667370244081%)

NIFTYPHARMA

Nifty Pharma
18404.6
  -121.150000000001 (-0.653954630716713%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17095.3
  -58.5 (-0.341032307710243%)

NIFTYSMALL

NIFTY Smallcap 100
16270.4
  -15.9500000000007 (-0.0979347735987512%)

NIFTYSMALLCAP250

Nifty Smallcap 250
15162.2
  -18.3999999999996 (-0.121207330408546%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14099.7
  15.1000000000004 (0.107209292418675%)

NIFTYHEALTH

Nifty Healthcare Index
11625.45
  -46.75 (-0.400524322749785%)

NIFTYTOTALMCAP

Nifty Total Market index
11455.35
  32.3999999999996 (0.283639515186529%)

NIFTYSMALLCAP50

Nifty Smallcap 50
7585.8
  -10.5999999999995 (-0.139539782001996%)

MIDCAP

S&P Bse Mid Cap
40004.52
  -155.140000000007 (-0.386308051412798%)

BSE HC

S&P Bse Healthcare
34422.67
  -152.889999999999 (-0.442190958006172%)

BSE500

S&P Bse 500
32199.48
  102.119999999999 (0.318157007305264%)

MSL400

S&P Bse 400 MidSmallCap
10402.68
  -26.9200000000001 (-0.258111528725935%)

ALLCAP

S&P Bse Allcap
9386.8
  27.2999999999993 (0.291682247983327%)

SML250

S&P Bse 250 SmallCap
6109.85
  -9.75 (-0.159324138832606%)

SPBSMOIP

S&P Bse Momentum
1941.21
  -8.26999999999998 (-0.424215688286111%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
9508.32
  33.8799999999992 (0.357593694191949%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
11408.38
  -23.2900000000009 (-0.203732263090173%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0.97%
3 Year6.99%
5 Year8.29%

Profit Growth

1 Year-39.49%
3 Year-3.72%
5 Year3.57%

ROE%

1 Year6.98%
3 Year10.48%
5 Year11.11%

ROCE %

1 Year8.58%
3 Year11.46%
5 Year11.99%

Debt/Equity

0.1766

Price to Cash Flow

19.6

Interest Cover Ratio

8.60035006962711

CFO/PAT (5 Yr. Avg.)

1.03940741325724

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 46.64 0
Dec 2023 46.65 0
Sep 2023 46.65 0
Jun 2023 46.65 0
Mar 2023 46.65 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 8.60035006962711.
  • The company has an efficient Cash Conversion Cycle of -77.738751933438 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.03940741325724.

 Limitations

  • The company has shown a poor profit growth of -3.72438429068539% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.9886512407408% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 2161.47 1939.05 2144.38 2233.42 1365.1
Total Expenditure 1722.63 1721.38 1659.39 1789.93 1549.36
Operating Profit 438.84 217.67 485 443.49 -184.27
Other Income 89.73 232.97 49.36 73.58 258.82
Interest 55.72 58.86 61.93 58.19 73.6
Depreciation 46.22 46.73 48.75 49.85 51.16
Exceptional Items 162.5 -658.37 -31.63 -19.67 -25.28
Profit Before Tax 589.13 -313.33 392.04 389.37 -75.5
Tax 158.62 -175.86 120.39 87.01 -55.09
Profit After Tax 430.5 -137.47 271.66 302.35 -20.41
Adjusted EPS (Rs) 15.26 -4.87 9.63 10.72 -0.72

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 6304.87 6712.63 7567.93 8141.58 8220.66
Total Expenditure 4977.39 5408.4 5677.59 6453.36 6747.9
Operating Profit 1327.48 1304.23 1890.34 1688.22 1472.77
Other Income 475.61 606.79 396.24 614.63 985.94
Interest 223.81 256.39 265.9 236.04 206.82
Depreciation 106.28 138.54 150.82 159.7 184.15
Exceptional Items 345.19 18.55 73.89 430.33 -495.87
Profit Before Tax 1818.18 1534.64 1943.76 2337.45 1571.87
Tax 329.88 180.1 294.31 339.66 363.11
Net Profit 1622.11 1354.55 1649.45 1997.79 1208.77
Adjusted EPS (Rs.) 52.74 48 58.46 70.8 42.84

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 11913.87 13198.05 14781.29 16710.37 17849.25
Borrowings 2831.45 3131.17 3112.58 2571.74 2660.82
Other N/C liabilities -623.63 389.35 1150.51 1412.85 1413.84
Current liabilities 2280.65 2991.54 3934.34 4896.21 4972.97
Total Liabilities 16430.56 19738.33 23006.93 25619.39 26925.1
Assets
Net Block 1413.48 1611.95 1722.49 1752.33 1745.94
Capital WIP 209.18 152.5 93.31 101.17 159.07
Intangible WIP 77.02 47.52 38.09 7.87 13.27
Investments 3268.75 4713.93 6989.95 8559.39 10334.01
Loans & Advances 6306.95 8182.74 7818.27 9335.01 8954.1
Other N/C Assets 14.04 2.78 4.72 5.55 2.33
Current Assets 5141.15 5026.92 6340.11 5858.08 5716.37
Total Assets 16430.56 19738.33 23006.93 25619.39 26925.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 2021.02 1534.64 1943.76 2337.45 1571.87
Adjustment -354.75 -107.18 235.11 -617.5 122.48
Changes in Assets & Liabilities 1221.78 491.01 -599.61 -113.17 196.13
Tax Paid -398.47 -339.35 -335.84 -390.72 -416.42
Operating Cash Flow 2489.58 1579.12 1243.42 1216.07 1474.06
Investing Cash Flow -2255.53 -1607.41 -1235.19 -897.02 -431.52
Financing Cash Flow -155.11 -139.42 -80.79 -305.12 -978.5
Net Cash Flow 78.95 -167.71 -72.57 13.93 64.05

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 46.65 46.65 46.65 46.65 46.64
blanche elizabeth saldanh... 0.39 0.39 0.39 0.39 0.39
cherylann maria pinto 0.27 0.27 0.27 0.27 0.27
glenn mario saldanha 0.35 0.35 0.35 0.35 0.35
neha saldanha 0.01 0.01 0.01 0.01 0.01
robin joseph pinto 0.18 0.18 0.18 0.18 0.18
saldanha family trust 45.45 45.45 45.45 45.45 45.45
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 53.35 53.35 53.35 53.35 53.36
aditya birla sun life tru... 2.26 2.31 2.43 2.59 2.06
ashish dhawan 2.55 2.55 2.55 2.55 2.55
ellipsis partners llc 1.68 1.68 1.68 1.68 1.68
government pension fund g... - 2.26 2.26 2.26 3.14
hdfc mutual fund - hdfc m... - - - - 2.54
icici prudential mnc fund... - - - - 1.23
investor education and pr... 0.09 0.09 0.08 0.09 0.09
smallcap world fund, inc - 4.52 4.84 4.84 3.47
hdfc mutual fund-hdfc arb... - - 2.21 2.40 -
icici prudential pharma h... - - - 1.24 -
wgi emerging markets smal... 1.22 1.26 1.17 1.03 -
life insurance corporatio... 2.93 2.22 1.57 - -
hdfc mutual fund - hdfc s... - 2.19 - - -
ntasain discovery master ... 2.02 1.46 - - -
hdfc large and mid cap fu... 2.34 - - - -
hsbc pooled investment fu... 2.39 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • ConcallQ1FY24 20 Jul 2023
  • PresentationQ3FY24 19 Feb 2024
  • PresentationQ3FY19 9 Jan 2020
  • PresentationQ2FY24 24 Nov 2023
  • PresentationQ1FY24 25 Sep 2023

Company News

Glenmark Pharmaceuticals informs about completion of tenure of independent directors1 Apr 2024, 10:45AM Glenmark Pharmaceuticals informs about disclosure6 Mar 2024, 5:27PM Glenmark Pharmaceuticals informs about transcript of earnings call19 Feb 2024, 2:41PM Glenmark Pharma - Quaterly Results13 Feb 2024, 1:38PM Glenmark Pharmaceuticals partners with Pfizer to launch Abrocitinib in India 31 Jan 2024, 6:03PM Glenmark, Ichnos launch alliance to accelerate new drug discovery in cancer treatment 30 Jan 2024, 5:35PM Glenmark Pharmaceuticals informs about media release25 Jan 2024, 10:19AM Glenmark Pharmaceuticals’ arm signs license agreement with Jiangsu Alphamab, 3DMed 25 Jan 2024, 9:20AM Glenmark Pharmaceuticals informs about media release 3 Jan 2024, 9:31AM Glenmark Pharmaceuticals launches biosimilar of popular anti-diabetic drug Liraglutide in India 3 Jan 2024, 9:21AM Glenmark Pharmaceuticals recalling 5,856 bottles of Deferasirox tablets in US market23 Nov 2023, 2:58PM Glenmark Pharmaceuticals reports consolidated net loss of Rs 61.56 crore in Q2FY2413 Nov 2023, 11:59AM Glenmark Pharma - Quaterly Results10 Nov 2023, 6:57PM Glenmark Pharma - Quaterly Results10 Nov 2023, 6:57PM Glenmark Pharmaceuticals gets USFDA’s final approval for Fluphenazine Hydrochloride Tablets7 Nov 2023, 9:24AM Glenmark Pharmaceuticals informs about media release18 Oct 2023, 9:56AM Glenmark Pharmaceuticals launches Triple-drug FDC of Teneligliptin with Dapagliflozin and Metformin 18 Oct 2023, 9:19AM Glenmark Pharmaceuticals informs about media release17 Oct 2023, 10:06AM Glenmark Pharmaceuticals gets final nod for Apremilast Tablets17 Oct 2023, 9:29AM Glenmark Pharmaceuticals informs about media release12 Oct 2023, 9:50AM Glenmark Pharmaceuticals’ arm signs agreement for OX40 antagonist monoclonal antibody portfolio12 Oct 2023, 9:25AM Glenmark Pharmaceuticals informs about media release27 Sep 2023, 2:23PM Glenmark’s arm inks distribution, license agreements with Cosmo for Winlevi27 Sep 2023, 12:06PM Glenmark Pharmaceuticals informs about withdrawal of issuer rating 23 Sep 2023, 10:38AM Glenmark Pharmaceuticals to divest 75% stake in Glenmark Life Sciences22 Sep 2023, 10:00AM Glenmark Pharmaceuticals aims to grow revenues by 10-11% in FY24 11 Sep 2023, 9:41AM Glenmark Pharmaceuticals informs about newspaper publication6 Sep 2023, 2:31PM Glenmark's arm recalls 1,200 bottles of Trandolapril & Verapamil Hydrochloride extended-release tablets28 Aug 2023, 4:10PM Glenmark Pharmaceuticals informs about press release22 Aug 2023, 10:04AM Glenmark Pharmaceutical informs about media release17 Aug 2023, 10:08AM Glenmark Pharmaceuticals gets USFDA’s final nod for Tacrolimus Ointment, 0.03%17 Aug 2023, 9:21AM Glenmark Pharma - Quaterly Results11 Aug 2023, 6:01PM Glenmark Pharma - Quaterly Results11 Aug 2023, 6:01PM Glenmark Pharmaceuticals partners with OMRON Healthcare India4 Aug 2023, 11:18AM Glenmark Pharmaceuticals informs about media release1 Aug 2023, 9:55AM Glenmark Pharmaceuticals gets USFDA’s final approval for Saxagliptin Tablets1 Aug 2023, 9:23AM Glenmark Pharmaceuticals informs about press release6 Jul 2023, 2:01PM USFDA issues warning letter to Glenmark Pharmaceuticals’ Monroe facility22 Jun 2023, 10:29AM Glenmark Pharmaceuticals reduces price of breast cancer drug Trastuzumab15 Jun 2023, 4:28PM Glenmark Pharmaceuticals informs about disclosure of related party transactions20 May 2023, 10:18AM Glenmark Pharma - Quaterly Results19 May 2023, 7:00PM Glenmark Pharma - Quaterly Results19 May 2023, 7:00PM Glenmark Pharmaceuticals incorporates wholly-owned subsidiary15 May 2023, 9:40AM Glenmark to pay $87.5 million to settle lawsuits related to generic drug in US 26 Apr 2023, 12:59PM Glenmark Pharmaceuticals informs about media release23 Mar 2023, 9:55AM Glenmark Pharmaceuticals gets USFDA’s approval for Calcipotriene and Betamethasone Dipropionate Foam23 Mar 2023, 9:18AM Glenmark Pharmaceuticals informs about media release20 Mar 2023, 9:59AM Glenmark Pharmaceuticals gets USFDA’s approval for Prochlorperazine Maleate Tablets 20 Mar 2023, 9:19AM Glenmark Pharmaceuticals’ arm gets USFDA’s approval for GRC 5427616 Mar 2023, 4:51PM Glenmark Pharmaceuticals informs about press release14 Mar 2023, 2:57PM

Glenmark Pharma Stock Price Analysis and Quick Research Report. Is Glenmark Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Glenmark Pharma cash from the operating activity was Rs 1474.063 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Pharma has a Debt to Equity ratio of 0.1766 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Pharma , the EPS growth was -39.4946956888966 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Pharma has OPM of 17.9154306550981 % which is a good sign for profitability.
     
  • ROE: Glenmark Pharma have a poor ROE of 6.98489048196142 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Glenmark Pharma is Rs 1026.4. One can use valuation calculators of ticker to know if Glenmark Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Glenmark Pharma

Glenmark Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the Glenmark Pharmaceuticals Ltd stock analysis page tailored for college student stock investors seeking comprehensive insights. In this section, we will delve into various aspects of Glenmark Pharmaceuticals Ltd, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders. Our objective is to equip you with valuable information to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Share Price Analysis 

Evaluate the share price of Glenmark Pharmaceuticals Ltd to gauge its market performance. Utilize Ticker pre-built screening tools to assess the current stock price and compare it with industry peers. Leverage our platform's market trends and indicators to aid your analysis as a college student stock investor seeking to assess the potential of this stock.

Glenmark Pharmaceuticals Ltd Balance Sheet Evaluation 

Evaluate the balance sheet of Glenmark Pharmaceuticals Ltd to understand the company's financial stability and performance. Leverage our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, to calculate the fair value based on the balance sheet. These tools provide a comprehensive view of the company's financials, empowering you to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Annual Report Review 

Access the annual reports of Glenmark Pharmaceuticals Ltd for valuable insights into the company's performance, strategies, and future prospects. Downloadable versions of the annual reports are available on Ticker, facilitating thorough analysis. College student stock investors will find these reports invaluable for understanding the company's long-term vision and growth trajectory.

Glenmark Pharmaceuticals Ltd Dividend Analysis 

Evaluate the dividend policy and history of Glenmark Pharmaceuticals Ltd. Ticker pre-built screening tools assist in analyzing the company's dividend payment history and potential. Monitor the dividend yield to assess the income potential associated with this stock. Dividend analysis is essential for college student stock investors, as it provides insights into how the company rewards its shareholders.

Glenmark Pharmaceuticals Ltd Quarterly Results Examination 

Analyze the quarterly financial results of Glenmark Pharmaceuticals Ltd to evaluate its performance and growth trends. Our premium features, such as DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, facilitate fair value calculations based on the quarterly results. This analysis delves into the company's revenue, expenses, and profitability.

Glenmark Pharmaceuticals Ltd Stock Price Monitoring 

Stay updated on the stock price of Glenmark Pharmaceuticals Ltd and track market trends. Our platform provides a detailed stock price chart, enabling historical data analysis and identification of patterns and trends. Understanding the stock's performance over time is crucial for college student stock investors seeking to make well-informed investment decisions.

Glenmark Pharmaceuticals Ltd Price Chart Analysis 

Analyze the price chart of Glenmark Pharmaceuticals Ltd to identify patterns and trends that can influence investment decisions. Ticker user-friendly interface allows for visual exploration of the stock's historical performance, enhancing understanding of market dynamics. Utilize this information to identify potential entry and exit points.

Glenmark Pharmaceuticals Ltd News Updates 

Stay updated with the latest news articles about Glenmark Pharmaceuticals Ltd. Ticker dedicated news section on the website offers valuable information on the company's recent developments, market trends, and industry updates. Staying informed is pivotal for college student stock investors looking to make sound investment decisions amid the dynamic market landscape.

Glenmark Pharmaceuticals Ltd Conference Call Transcripts 

Access conference call transcripts of Glenmark Pharmaceuticals Ltd to gain insights into the company's operations, strategies, and future plans. These transcripts comprehensively outline key discussions and announcements made during the company's conference calls. Utilize this information to gain a deeper understanding of the company's direction and prospects.

Glenmark Pharmaceuticals Ltd Investor Presentations 

Explore investor presentations of Glenmark Pharmaceuticals Ltd to obtain valuable insights into the company's growth potential and investment opportunities. These presentations provide an overview of the company's value proposition, strategies, and financial performance. Analyzing investor presentations can offer college student stock investors a better understanding of the company's vision and plans.

Glenmark Pharmaceuticals Ltd Promoters & Shareholders 

Understand the ownership structure of Glenmark Pharmaceuticals Ltd by reviewing its key promoters and major shareholders. Gain insights into ownership concentration and potential alignment of interests. Ticker provides detailed information about the company's promoters and major shareholders, enabling informed investment decisions and understanding of the key stakeholders driving the company's growth.

Read More
X